from be recap Today, quarter I'll therapy more adoption. answering Good to we and welcome detail in our on questions. Investor pipeline forward slides share and Zach and presentation our Michaella. detail driving Relations QX on site. we call. the you, our cover referring your will financials it's to clinical our everyone, our look fourth how afternoon results, Thank to will
Turning to X. Slide
can't. is paradigm Through we'll than mission Our more reported the others over treated has critical X,XXX what improving patients care data outcomes. depth more having later This of MRIdian XX,XXX year-end, and changing them of to clinically of share in the prove to treat growing body is and with call.
to turn In ended business. the Slide results our year solid QX five Let's performance received MRIdian on we the the X. orders. quarter, with across We
propositions region achievements. and and is are clinical, We with and of are Eindhoven our Hospital MRIdian's value pleased how purchases value In Netherlands, Evidence the economic the the commercial recent MRIdian. our in strategic, of Catharina traction largest our resonating. evident prestigious
second top Hoag have. their first a patients. Amsterdam about excited system surpassed added SNUH the and As in X,XXX-patient Henry facility, Jefferson State treated Hospital Korea Ford will they each patient the and Thomas South impact both and Penn UMC we're milestone. and University training MRIdian their
revenue. $XX.X million three to at days. date marked recognized our also installation including working XX to We one revenue system Turning QX units, upgrade. fastest primarily from
particular, operationally. serving We we're continue training focused better our improve and In on customers. to
have $XXX continue cancellations about to system We and removed grown has million. backlog one zero the Our to quarter to COVID-XX. in due order
we approximately cash, $X Regarding used million.
progress financial past cash significant years, Over has on driven reducing few burn. the discipline
sheet recent and innovation and significant runway pipelines. clinical capital topped the commercial off raise balance progress make our Our on provides to us
solidly executed As we the face look back in on pandemic. the of XXXX, we
solid MRIdian top is systems, process is uncertainty, more economics I significantly at several we've setup that we ongoing believe our driven to for lead. to burn it clinical have is meaningful that and allocating and extend protect installing systems our summary, customers for innovation adoption next a guidance the and our and I and we've we're are shareholder over prudent cash value provide purchase MRIdian feel the faster, driving and driving to XXXX time. In customers, line bottom years. can rigor say, due improved seeing What that However, this not therapy capital incremental we
slide X. Turning to
clinical accrue to and commercial Our traction. pipelines innovation
driving automation. front, of our imaging, and times are increased sub-XX-minute the future, On goal package brain MRI improving can the treatment workflow In toward dosing, remote enhanced a treatment and innovation we expect you access. and
time. it concurrently context, work are We go is efficiencies therapy With into central deeper margin improve cost our to to as driving let's broad clinical over driving that adoption.
represent critical to customers implants one, the The and frontline These no fractions also very meaningful low-to-no Slide is has X. data. our dose, number Customer fewer slide one MRIdian of and tight success. number Moving clear grade goals Ablative clinical which demonstrates been X. two, They to define our five how MRIdian clinical input expand how therapy. are, become pipeline therapy. desire shaped expands and or elements have radiation utility toxicity. the utilization number seven about SMART MRIdian of margins, thing they the clinical three
levels candidates At been concern underutilized paradigm couldn't to cancer opportunity share soft tumors and moving customer to cancer systems, value MRIdian leading consistently catchment the in center a few expands on is toxicity. They had were generally examples. note to treated cancer previously. treating tissue trade-off limited the who and travel the areas healthy how this with for radiation site healthy value patients from treating radiation not and believe referrals. now, include that IMRT, in same depicts that And with X delivery of drive the translates of as AUMC A to It's patient were tumor trade-off. historically the RO is pandemic, Conventional strategic overall risk. kidney to the time, versus today, in other been SBRT, now APM with outside patients has MRIdian. types yields customers dose for short-course important economic in from clinical stands therapy. old and key slide into this in increasing in-network adding accelerate improved wouldn't that in for candidates due treatments, will treated to adding likely the high-dose, SBRT about IMRT technology to a Prior data, form on The desire paradigm it Slide and practice. As X have high of risk SBRT. or MRIdian they at MRIdian their treatment Clinical patients the tissue radiation tissue radiating customers treat due prior MRIdian, organically are trend. patients to how of generally outcomes. therapy. US the patients shifting to the organs not shift enables not market the couple pancreas Moffitt, it's that of radiation
in our time XX% utilized market early versus MRIdian, of the even SBRT see days XX%. overall You over the customers about of of the
of is percentage our IMRT customer are dramatically. are ablative, MRIdian XX% driving rate. treatment. systems. remarkable sparingly and treated what utilizes SBRT safe, market enables customers As increased confidence market conventional patients toward knowledge via utilizing SBRT The nearly over that MRIdian of market the grew, It Today, short-course nearly the with as five completely the is as times SBRT noninvasive
We Dr. CT is radiotherapy, has of at future As that on has business "the Dr. precursor Steinberg XX so which believe were the two has obsolete. to patients growth dramatic MRIdian, it's by shared to of x-rays this a said, grown CAGR interesting this technology will just CT-guided to growth. a ultimate Haas-Kogan render SBRT machine". day XX% MR-guided Slide replaced dimensional On treated note be MRIdian And one. since
demonstrating successful Our program are to and lead can that customers does another. one MRIdian increasingly
Our innovation therapy clinical drive adoption. and to pipelines will continue
XX. Slide to Turning
strategy. step take view to back clinical a our Let's
out this by led also to prostate, pancreas, have meaningful MRIdian unmet data stands of these customers Our areas clinical tumors. journey application tough-to-treat the an We demonstrating generate in MRIdian there lung key brain. our need targets in and in is cancer They in and types. beachhead adjacent that signal believe value aim of
Staying As expanded our prostate, II an process curiosity. SMART to clinical is in pancreas breadth trial, work can confirmatory reflects the customers leads The than represents predominantly trials. XX, level effort value have feasibility this to interesting proof XX When Phase Slide the clinical Phase III. of the trials. conducting by investigator Phase on result Currently kidney. over we and an in definitive that progresses signal are required, led. pipeline customers view extraordinary Other developing macro I at that of example, work proving longitudinally. to depth
pancreas frontline has Let's of delivered of more SMART how trials example Slide proof clinical view signal toxicity XX to and aggregate road driving went importantly, about not to how signal Also zero. that randomized doses led The two or only high ablative higher are double powerful. was high-dose disease. an with process the therapy. Customers Retrospective depicts went to was this the for customers This spectrum path grade work began low-dose map than two-year multiyear us trial. patients The body down the a pancreas. three of in the takes survival but span trial. XX% systems. This conventional down to controlled led very in
where care in standard first metastatic is The SMART. of chemotherapy care is MRIdian compared of standard plus late-stage to cancer
or inoperable medically robust patients SMART. XX to a intend of management patients protocol symptom down pipeline. Slide compares these MRIdian that operable boiled for We for is typical cancer second therapy otherwise. as is pancreatic MRIdian establish our The the data versus frontline view
conventionally trial has delivered discuss just randomized let's targets: we opened to clinical road key UCLA first the map. for patients, pancreas, SBRT. MRIdian two head-to-head As SMART are assess shared prostate controlled versus There in intact a
Second, frontline we can fraction prostatectomy therapy Cornell five of controlled expanding patients, trial fractions as compare disease versus therapy. to SMART. post at Like for MRIdian believe a that randomized a conventional opened spectrum the has MRIdian dose position XX pancreas,
through execution moving we're the and studies confirmatory lung phase Next, metastatic for cancers. in
courses XX, for shorter treatment. Slide are patients on effective pushing Finally of
allows to MRIdian clinicians SBRT technology continuum the to IMRT to along SMART. move from Our
and us year leading in in The adrenal value, on In clinical ONE slide our both single single Our kidney, customers enrollment trial XX, and pancreas, are value. for lymph MRIdian work SMART. located SMART primary opens summary which oligomets yields this strategic economic drives now exploratory tumors liver, nodes. with fraction lung, value to fraction therapy
on net patients in who treatment from in-network MRIdian be travel catchment the that The and form referrals. share Our wouldn't for attracting system, they multiple areas proof increasing buying systems. new patients customers is that patients outside incremental couldn't or in customers of are in treated another
our pipelines. and made propositions value meaningful progress have across business, We
discuss now to We our to are improve for positioned it With turn financials. I'll care over Zach to well that patients cancer globally.
